Dundas Partners LLP increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 38,568 shares of the medical research company’s stock after buying an additional 350 shares during the period. Thermo Fisher Scientific accounts for about 2.6% of Dundas Partners LLP’s portfolio, making the stock its 18th largest holding. Dundas Partners LLP’s holdings in Thermo Fisher Scientific were worth $11,325,000 as of its most recent filing with the SEC.
Several other hedge funds also recently made changes to their positions in the stock. BlackRock Inc. boosted its holdings in shares of Thermo Fisher Scientific by 4.1% during the 1st quarter. BlackRock Inc. now owns 27,251,678 shares of the medical research company’s stock worth $7,459,327,000 after buying an additional 1,074,400 shares during the period. FMR LLC boosted its holdings in shares of Thermo Fisher Scientific by 33.5% during the 1st quarter. FMR LLC now owns 11,572,581 shares of the medical research company’s stock worth $3,167,647,000 after buying an additional 2,900,868 shares during the period. Clearbridge Investments LLC boosted its holdings in Thermo Fisher Scientific by 2.4% in the 1st quarter. Clearbridge Investments LLC now owns 3,089,195 shares of the medical research company’s stock valued at $845,574,000 after purchasing an additional 71,898 shares during the period. Janus Henderson Group PLC boosted its holdings in Thermo Fisher Scientific by 22.9% in the 2nd quarter. Janus Henderson Group PLC now owns 2,986,916 shares of the medical research company’s stock valued at $877,186,000 after purchasing an additional 555,802 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in Thermo Fisher Scientific by 0.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,706,326 shares of the medical research company’s stock valued at $605,651,000 after purchasing an additional 17,860 shares during the period. 88.21% of the stock is owned by institutional investors and hedge funds.
In other news, Director C Martin Harris sold 275 shares of the stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $270.73, for a total transaction of $74,450.75. Following the completion of the sale, the director now directly owns 6,433 shares in the company, valued at $1,741,606.09. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction on Tuesday, July 30th. The stock was sold at an average price of $284.83, for a total transaction of $14,241,500.00. Following the sale, the chief executive officer now owns 342,193 shares of the company’s stock, valued at $97,466,832.19. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 52,775 shares of company stock valued at $14,986,676. 0.45% of the stock is currently owned by corporate insiders.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.01 by $0.03. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.11%. The firm had revenue of $6.32 billion during the quarter, compared to analysts’ expectations of $6.31 billion. During the same period in the prior year, the company posted $2.75 EPS. The company’s revenue was up 3.9% on a year-over-year basis. On average, analysts expect that Thermo Fisher Scientific Inc. will post 12.23 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Tuesday, September 17th will be given a $0.19 dividend. This represents a $0.76 annualized dividend and a yield of 0.28%. The ex-dividend date of this dividend is Monday, September 16th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 6.83%.
A number of analysts have issued reports on TMO shares. Argus boosted their price objective on shares of Thermo Fisher Scientific from $285.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $299.00 price objective for the company in a report on Wednesday, June 12th. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a report on Thursday, May 30th. They issued an “outperform” rating for the company. Barclays set a $330.00 price objective on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a report on Monday, July 15th. Finally, BTIG Research boosted their price objective on shares of Thermo Fisher Scientific to $320.00 and gave the company a “buy” rating in a report on Thursday, May 23rd. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and an average target price of $303.17.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Featured Story: Balanced Fund
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.